Loading...
•
Dec 31, 2024
PetMed Express Q3 2025 Earnings Report
Reported a decrease in net sales but an increase in gross margin rate and adjusted EBITDA compared to the prior year period.
Key Takeaways
PetMed Express reported third-quarter results with net sales of $53.0 million. The company achieved an adjusted EBITDA of $2.0 million, a $1.1 million improvement year-over-year, while reducing G&A expenses by $2.6 million compared to last year. The gross margin rate increased by 80 basis points compared to the prior year period.
Net sales reached $53.0 million.
Gross margin rate increased by 80 basis points compared to the prior year period, reaching 28.1%.
Adjusted EBITDA was $2.0 million, compared to $0.9 million in the prior year period.
G&A expenses were reduced by $2.6 million compared to last year.
PetMed Express
PetMed Express
Forward Guidance
The company did not provide specific forward guidance in the earnings report. The focus is on long-term success through operational excellence and financial discipline.